ICON wins multiple categories in 2021 CRO Leadership Awards for the fourth year in a row
April 20 2021 - 4:35AM
Business Wire
ICON recognised for specialised services
offering across product development lifecycle, winning five awards
overall
ICON plc, (NASDAQ: ICLR) ICON plc, a global provider of
drug development and commercialisation services to the
pharmaceutical, biotechnology and medical device industries, has
won multiple categories in the annual CRO Leadership Awards.
This is the fifth year ICON has enjoyed success in the CRO
Leadership Awards, having won multiple categories previously in
2020, 2019, 2018 and 2015.
ICON received 2021 CRO Leadership Awards in five of the overall
six categories, each further divided into three groups – Big
Pharma, Small Pharma, and Overall. In two categories, ICON achieved
awards in both the Big Pharma and Overall groups.
Winning categories:
- Capabilities (Big Pharma)
- Compatibility (Overall, Big Pharma)
- Expertise (Big Pharma)
- Reliability (Big Pharma)
- Quality (Overall, Big Pharma)
Life Science Leader magazine and Clinical Leader once again
teamed up with Industry Standard Research (ISR) to determine the
award recipients. They assessed sixty contract research
organisations on over 20 performance metrics in ISR’s annual CRO
Quality Benchmarking survey.
Survey participants were recruited from pharma and biopharma
companies of all sizes and were screened for decision-making
influence related to working with contract research
organisations.
Dr Steve Cutler, Chief Executive Officer, ICON plc, said: “We
are pleased to have been honoured with CRO Leadership Awards for
the fourth year in a row. These awards are a recognition of ICON’s
top-performing scientific specialists and operational
professionals, and demonstrate the consistent quality we offer our
sponsors year in, year out, at all levels of the industry and
across multiple clinical areas.”
“These award winners have proven themselves to be the top
service providers in each category, said Ed Miseta, chief editor
for Clinical Leader. “I congratulate all of them for work ethic
they exhibit in consistently meeting the needs of their drug
development clients."
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards.
About ICON plc
ICON is a global provider of consulting, and outsourced
development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. ICON’s focuses on the factors that are critical to
clients – reducing time to market, reducing cost and increasing
quality – and its global team of experts has extensive experience
in a broad range of therapeutic areas. ICON has been recognised as
one of the world’s leading Contract Research Organisations through
a number of high-profile industry awards. With headquarters in
Dublin, Ireland, ICON employs approximately 16,000 employees in 93
locations in 41 countries. Further information is available at
www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210420005138/en/
ICON Media Contact Hannah Myers Weber Shandwick
Telephone: +44(0)2033 538760 hmyers@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Sep 2023 to Sep 2024